tiprankstipranks
Purple Biotech’s Phase 2 pancreatic cancer study selected as presentation
PremiumThe FlyPurple Biotech’s Phase 2 pancreatic cancer study selected as presentation
4d ago
Bristol Myers lowers FY24 adjusted EPS view to 40c-70c, consensus 65c
PremiumThe Fly
Bristol Myers lowers FY24 adjusted EPS view to 40c-70c, consensus 65c
4d ago
Bristol Myers reports Q1 adjusted EPS ($4.40), consensus ($4.44)
PremiumThe Fly
Bristol Myers reports Q1 adjusted EPS ($4.40), consensus ($4.44)
4d ago
Bristol Myers and Cellares sign $380M agreement for CAR T cell therapies
PremiumThe FlyBristol Myers and Cellares sign $380M agreement for CAR T cell therapies
7d ago
Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
PremiumMarket News
Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
7d ago
Bristol Myers price target raised to $52 from $51 at Wells Fargo
PremiumThe Fly
Bristol Myers price target raised to $52 from $51 at Wells Fargo
11d ago
Standard BioTools announces multi-year agreement with Bristol Myers
PremiumThe FlyStandard BioTools announces multi-year agreement with Bristol Myers
25d ago
Bristol Myers: European Commission expands approval of Reblozyl
PremiumThe Fly
Bristol Myers: European Commission expands approval of Reblozyl
26d ago
Zai Lab, Bristol Myers: Krazati confirmatory trial meets PFS primary endpoints
PremiumThe Fly
Zai Lab, Bristol Myers: Krazati confirmatory trial meets PFS primary endpoints
28d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100